Clinical use of statins during coronary artery bypass grafting
Article Sidebar
Main Article Content
Abstract
The review summarizes current data on the use of statins in patients with coronary heart disease when performing coronary artery bypass grafting. The information about the mechanisms of action of statins, principles of pre- and postoperative usage, in particular, the duration of administration and dosage, is provided. The beneficial effect of statins in preventing of complications are associated with their non-lipid properties: inhibition of inflammation in the vascular wall, endothelial function improvement, reducing of platelet aggregation and smooth muscle cells proliferative activity. In many clinical trials, statin treatment reduced the risk of postoperative atrial fibrillation, myocardial infarction, stroke and death, allowed to reduce the length of stay in the intensive care and hospital treatment. However, the appointment of high-intensity statin therapy was associated with increased frequency of renal failure. The lack of sufficient evidence base and uncertainty of recommendations lead to insufficient use of these drugs in clinical practice.
Article Details
Keywords:
References
Athyros V.G., Papageorgiou A.A., Mercouris B.R. et al. Treatment with atorvastatin to the National cholesterol educational program goal versus «usual» care in secondary coronary heart disease prevention: The GREek Atorvastatin and Coronary-heart-disease Evaluation Study (GREACE) // Cur. Med. Res. Opin.– 2002.– Vol. 18.– P. 220–228.
Barakat A.F., Saad M., Abuzaid A. et al. Perioperative Statin Therapy for Patients Undergoing Coronary Artery Bypass Grafting // Ann. Thorac. Surg.– 2016.– Vol. 101 (2).– P. 818–825.
Caorsi C., Pineda F., Munoz C. Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass // Eur. Cytokine Netw.– 2008.– Vol. 19 (2).– P. 99–103.
Charalambos A., Demosthenous M., Reilly S. et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery: Effects of short-term pre-operative statin treatment // J. Amer. Coll. Cardiology.– 2012.– Vol. 59 (1).– P. 71–73.
Chello M., Anselmi A., Spadaccio C. et al. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery // Ann. Thorac. Surg.– 2007.– Vol. 83.– P. 1374–1380.
Chello M., Giuseppe P., Candura D. et al. Effects of atorvastatin on systemic inflammatory response after coronary artery bypass // Crit. Care. Med.– 2006.– Vol. 34.– P. 660–667.
Christenson J.T. Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization // Cardiovasc. Surg.– 2001.– Vol. 9.– P. 33–43.
Christenson J. T. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG // Eur. J. Cardiothorac. Surg.– 1999.– Vol. 15.– Р. 394–400.
Сlinicaltrials.gov/ct2/show/study/NCT01528709
Collard C.D., Body S.C., Shernan S.K. et al. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery // J. Thorac. Cardiovasc. Surg.– 2006.– Vol. 132.– P. 392–400.
Dereli Y., Ege E., Kurban S. et al. Pre-operative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass grafting // J. Int. Med. Res.– 2008.– Vol. 36.– P. 1248–1254.
Dotani M.I., Elnicki D.M., Jain A.C., Gibson C.M. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting // Am. J. Cardiol.– 2000.– Vol. 86.– P. 1128–1130.
ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart. J.– 2016.– Vol. 37.– Р. 2999–3058.
Filion K.B., Pilote L., Rahme E. et al. Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass graft surgery // J. Card. Surg.– 2008.– Vol. 23.– P. 209–215.
Go A.S., Mozaffarian D., Roger V.L. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association // Circulation.– 2014.– Vol. 129.– P. 28–292.
Higgins J.P.T, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1,0 [updated March 2011]. The Cochrane Collaboration, 2011, Available from www.handbook.cochrane.org.
Hillis L.D., Smith P.K., Anderson J.L. et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // J. Thorac. Cardiovasc. Surg.– 2012.– Vol. 143.– P. 4–34.
Kang S., Liu Y., Liu X.B. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials // Clin. Ther. – 2013.– Vol. 35 (8).– P. 1125–1136.
Kolh P., Windecker S., Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. J. Cardio-Thoracic. Surgery.– 2014.– Vol. 46.– Р. 517–592.
Kostapanos M.S., Liberopoulos E.N., Goudevenous J.A. et al. Do statins have an antiarrhythmic activity? // Cardiovas. Res.– 2007.– Vol. 75.– P. 10–20.
Kotseva K., Wood D., De Bacquer D. et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries // Eur. J. Prev. Cardiol.– 2016.– Vol. 23 (6).– Р. 636–648.
Krivoy N., Adler Z., Saloma R. et al. Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery // Exp. Clin. Cardiol.– 2008.– Vol. 13,
N 4.– P. 171–174.
Kuhn E.W., Slottosch I., Wahlers T., Liakopoulos O.J. Preoperative statin therapy for patients undergoing cardiac surgery // Cochrane Database Systematic Reviews.– 2015.– Vol. 8.– CD008493.
Kulik A., Brookhart M.A., Levin R. et al. Impact of statin use on outcomes after coronary artery bypass graft surgery // Circulation.– 2008.– Vol. 118.– P. 1785–1792.
Kulik A., Ruel M., Jneid H. Secondary prevention after coronary artery bypass graft surgery. A Scientific Statement from the American Heart Association // Circulation.– 2015.– Vol. 10.– Р. 927–964.
Kulik A., Voisine P., Mathieu P. et al. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial // Ann. Thorac. Surg. – 2011.– Vol. 92 (4).– P. 1284–1290.
Landoni G., Casso G., Gallo M. et al. Perioperative statin therapy in cardiac surgery: a meta-analysis of randomized controlled trials // Critісаl. Care.– 2016.– Vol. 20.– P. 395.
Laufs U., Adam Oliver. Acute effects of statins // J. Am. Coll. Cardiol.– 2012.– Vol. 59, N 1.– P. 71–73.
Liakopoulos O.J., Choi Y.H., Haldenwang P.L. et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30 000 patients // Eur. Heart J.– 2008.– Vol. 29 (12).– P. 1548–1559.
Liakopoulos O.J., Kuhn E.W., Hellmich M. et al.; StaRT-CABG Investigators. Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial // Am. Heart. J.– 2015.– Vol. 170 (1).– Р. 46–54.
MacCallum N.S., Finney S.J., Gordon S.E. et al. Modified criteria for the systemic inflammatory response syndrome (SIRS) improves their utility following cardiac surgery // Chest.– 2014.– Vol. 145.– P. 1197–1203.
Marin F., Pascual D.A., Roldan V. et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting // Am. J. Cardiol.– 2006.– Vol. 97.– P. 55–60.
Martínez-Comendador J.M.M., Alvarez J.R.R., Mosquera I. et al. Preoperative statin treatment reduces systemic inflammatory response and myocardial damage in cardiac surgery // Eur. J. Cardiothorac. Surg.– 2009.– Vol. 36.– P. 998–1005.
Mitchell L.B., Exner D.V., Wyse D.G. et al. Prophylacticoral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair // JAMA.– 2005.– Vol. 294.– P. 3093–3100.
Ozaydin M., Dogan A., Varol E. et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation // Cardiology.– 2007.– Vol. 107.– P. 117–121.
Pan W., Collard C.D., Coselli J. et al. Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery // The Annals of Thoracic Surgery.– 2017 Mar 15. pii: S0003-4975(17)30016-4. doi: 10,1016/j.athoracsur.2016.12,043. [Epub ahead of print]
Patti G., Chello M., Candura D. et al. Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 // Circulation.– 2006.– Vol. 114.– P. 145–1461.
Patti G., Chello M., Candura D. et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery // Crit. Care Med.– 2006.– Vol. 34 (3).– Р. 660–667.
Philip F., Blackstone E., Kapadia S.R. Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery // Cardiovasc. Diagn. Ther.– 2015.– Vol. 5 (1).– P. 8–16.
Plenge J.K., Hernandez T.L., Weil K.M. et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction // Circulation.– 2002.– Vol. 106.– P. 1447–1452.
Post Coronary Artery Bypass Graft Trial Investigartors. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenouse-vein coronary artery bypass grafts // New Engl. J. Med.– 1997.– Vol. 336.– P. 153–162.
Pretorius M., Donahue B.S., Yu C. et al. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass // Circulation.– 2007.– Vol. 116 (Suppl. 1).– P. 1–7.
Ridker P.M., Cannon C.P., Morrow D. et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy // New Engl. J. Med.– 2005.– Vol. 352, N 1.– Р. 20–28.
Roik M., Starczewska M.H., Huczek Z. Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function – a preliminary report // Circulation.– 2005.– Vol. 112 (3).– P. 357–363.
Sacks F.M., Pfeffer M.A., Moye L.A. et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels // New Engl. J. Med.– 1996.– Vol. 355.– Р. 1001–1009.
Suzumura K., Yasuhara M., Tanaka K. et al. Protective effect of fluvastatin sodium, HMG-CoA reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro // Biochem. Pharmacol.– 1999.– Vol. 57.– P. 697–703.
Tandon V., Bano G., Khajuria V. et al. Pleiotropic effects of statins// Ind. J. Pharmacology.– 2005.– Vol. 37, N 2.– P. 77–85.
Tuzcu E.M., Nissen S.E., Schoenhagen P. et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators // New Engl. J. Med.– 2005.– Vol. 352 (1).– Р. 29–38.
Walter D.H., Schachinger V., Elsner M. et al. Effect of statin therapy on restenosis after coronary stent implantation // Am. J. Cardiol.– 2000.– Vol. 85.– P. 962–968.
Warren O.J., Smith A.J., Alexiou C. et al. The inflammatory response to cardiopulmonary bypass: part 1 – mechanisms of pathogenesis // J. Cardiothorac. Vasc. Anesth.– 2009.– Vol. 23.– P. 223–231.
Weitz-Schmidt G., Welzenbach K., Brinkmann V. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin Site // Nat. Med.– 2001.– Vol. 7.– P. 687–692.
Zheng Z., Jayaram R., Jiang L. et al. Perioperative Rosuvastatin in Cardiac Surgery // New Engl. J. Med.– 2016.– Vol. 374.– P. 1744–1753.